Glucosamine sulfate 1g / Ascorbic acid 50mg tablets
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Glucosamine sulfate + Ascorbic acid on the MHRA register
Natures Aid Glucosamine sulfate 1000mg with Vitamin C 50mg tablets
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 6 · Randomised trials: 6 · 1975–2026
Showing the 50 most relevant studies, sorted by most relevant.
Mariyani N, Nuraida L, Lioe HN, et al.
2025
N. Kampa, Duangdaun Kaenkangploo, S. Jitpean, et al.
Frontiers in Veterinary Science, 2023
Boeri L, De Lorenzis E, Lucignani G, et al.
2024
- Urinary Tract Infections
- Ascorbic Acid
- Acetylglucosamine
A. Notarnicola, G. Maccagnano, L. Moretti, et al.
International Journal of Immunopathology and Pharmacology, 2016
Bun Kim, S. Lee, K. Han, et al.
Diseases of the Colon & Rectum, 2017
Songül Cömert Kılıç
Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2021
B. Tolbert, M. Downing, R. W. Carlson, et al.
Annals of the New York Academy of Sciences, 1975
Alfinaikh RS, Alamry KA, Hussein MA
2025
Sustainable biomaterials that are both efficient and environmentally friendly are the subject of research and development efforts among scientists and academics from a variety of contemporary scientific disciplines. Due to their significant involvement in several physiological and pathological processes, sulfated polysaccharides (SPs) have garnered growing interest across various application domains, including biomedicine. Nevertheless, mechanical and thermal stability are issues for unmodified polysaccharide materials. Interactions between polymers, such as the mixing of biopolymers with synthetic or biopolymers through chemical interaction or grafting into the main chain structure of raw materials to enhance their therapeutic effects, are essential to meet the high standards of biomedical features. Another way to improve the mechanical and thermal properties is to graft appropriate fillers onto the polysaccharide backbone. The characteristics of polysaccharide bio-nanocomposites in comparison to more traditional polymers have attracted a lot of interest. With an emphasis on anti-inflammatory, anticancer, antiviral, immunoregulatory, and anticoagulant properties, this review delves into the most recent biological uses of sulfated polysaccharides. As well as thoroughly outlining the factors that impact the biological properties, such as the extraction process, molecular weight (Mw), the degree of sulfation, distribution/position, modification procedures, and the filler size, etc., this review aims to: (1) provide a systematic and critical overview of the cutting-edge research on SPs and hybrid sulfated polysaccharide bio-nanocomposites; (2) identify the key factors, mechanisms, methods, and challenges impacting SPs bio-nanocomposites; (3) elucidate the current and potential biomedical applications, advantages, manufacturing challenges, and opportunities associated with SPs bio-nanocomposites; (4) offer insights into future research directions by suggesting improvements for bio-nanocomposites, including novel materials, and advanced processing techniques.
Abstract licence: CC BY
S. Nam, Sung Chul Park, Sung Joon Lee, et al.
Journal of Gastroenterology and Hepatology, 2021
Shiqing Zhou, Yanghai Yu, Weiqiu Zhang, et al.
Environmental science & technology, 2018
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.